RPL13AP25: A Promising Drug Target / Biomarker (G100287887)

Target Name: RPL13AP25

NCBI ID: G100287887

RPL13AP25

Other Name(s): ribosomal protein L13a pseudogene 25 | Ribosomal protein L13a pseudogene 25 | RPL13A_11_1314 | FWP004 | S863-4

RPL13AP25: A Promising Drug Target / Biomarker

Rpl13ap25 is a gene that encodes a protein known as Rpl13ap25. Rpl13ap25 is a member of the Rpl13 family, which is characterized by the presence of a unique nucleotide in the protein sequence that is not found in any other gene. The Rpl13ap25 gene has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Rpl13ap25 Protein

Rpl13ap25 is a 21-kDa protein that is expressed in various tissues and cells of the body. It is primarily localized to the endoplasmic reticulum (ER), where it is involved in the intracellular transport of various proteins and other macromolecules. Rpl13ap25 is composed of 129 amino acid residues and has a calculated pI of 5.5.

The Rpl13ap25 gene is located on chromosome 16 at position 1388.3. It is a single exon gene that encodes the Rpl13ap25 protein. The protein is made up of 129 amino acid residues, with the first amino acid residue being a glutamic acid (E), the second amino acid residue being a lysine (K), the third amino acid residue being a methionine (M), the fourth amino acid residue being a glutamine (Q), the fifth amino acid residue being a cysteine (C), the sixth amino acid residue being a glycine (G), the seventh amino acid residue being a proline (P), the eighth amino acid residue being a leucine (L), the ninth amino acid residue being a lysine (K), the tenth amino acid residue being a methionine (M), the eleventh amino acid residue being a glutamine (Q), the twelfth amino acid residue being a cysteine (C), and the thirteenth amino acid residue being a glycine (G).

The Rpl13ap25 gene

The Rpl13ap25 gene is a member of the Rpl13 family, which is characterized by the presence of a unique nucleotide in the protein sequence that is not found in any other gene. The Rpl13 family is named after the protein encoded by the Rpl13 gene, which is composed of 21 amino acids and has a calculated pI of 6.3.

The Rpl13ap25 gene is a single exon gene that encodes the Rpl13ap25 protein. It is located on chromosome 16 at position 1388.3 and has a calculated ORFSN of 1389. The gene has a single start codon (ATG) and a single stop codon (TAG), which are located at positions 2 and 138, respectively.

The Expression of Rpl13ap25

Rpl13ap25 is expressed in various tissues and cells of the body, including the brain, spinal cord, and skeletal muscles. It is primarily located to the ER, where it is involved in the intracellular transport of various proteins and other macromolecules.

The Rpl13ap25 protein is involved in various cellular processes, including intracellular signaling, protein transport, and cellular signaling pathways. It is a key protein in the regulation of cellular processes that are critical for maintaining cellular homeostasis and have implications for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug Targeting Rpl13ap25

Rpl13ap25 is a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique nucleotide and its involvement in cellular signaling pathways make it an attractive target for drug development.

One approach to targeting Rpl13ap25 is to use small molecules that can modulate its activity. Such

Protein Name: Ribosomal Protein L13a Pseudogene 25

The "RPL13AP25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL13AP25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets